Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer

European Journal of Cancer Part A

Volumn 33, Issue 1, 1997, Pages 115-121

  Angelopoulou, K ^a,b   Diamandis, E P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

ascites fluid; auto antibodies; ovarian cancer; p53; tumour markers; tumour suppressor genes

Indexed keywords

AUTOANTIBODY; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASCITES FLUID; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ASCITIC FLUID; AUTOANTIBODIES; BLOTTING, WESTERN; FEMALE; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031030551     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00295-X     Document Type: Article

References (28)

1. 1. Lane DP. Cancer. A death in the life of p53. Nature 1993, 362, 786-787.
2. 2. Lane DP. p53, guardian of the genome. Nature 1992, 358, 15-16.
3. 3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253, 49-53.
4. 4. Caron De Fromentel C, Soussi T. TP53 tumour suppressor gene: a model for investigating human mutagenesis. Genes Chrom Cancer 1992, 4, 1-15.
5. 5. Crawford L, Piw DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982, 30, 403-408.
6. 6. Caron De Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987, 39, 185-189.
7. 7. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53 HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992, 89, 3439-3442.
8. 8. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the p53 mutation. Cancer Res 1992, 52, 4168-4174.
9. 9. Schlichtholz B, Legros Y, Gillet D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992, 52, 6380-6384.
10. 10. Lubin R, Schlichtholz B, Bengoufa D, et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 1993, 53, 5872-5876.
11. 11. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994, 69, 809-816.
12. 12. Mudenda B, Green JA, Green B, et al. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 1994, 69, 1115-1119.
13. 13. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumour suppressor gene protein in various cancers. Int J Cancer 1994, 58, 480-487.
14. 14. Angelopoulou K, Stratis M, Diamandis EP. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 1997, 68, 1-6.
15. 15. Cannistra SA. Cancer of the ovary. N Engl J Med 1993, 329, 1550-1559.
16. 16. Okamoto A, Sameshima Y, Yokoyama S, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991, 51, 5171-5176.
17. 17. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991, 51, 2979-2984.
18. 18. Levesque MA, Katsaros D, Yu H, et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75, 1327-1338.
19. 19. Murakami Y, Hayashi K, Sekiya T. Detection of aberrations of the p53 alleles and the gene transcript in human tumour cell lines by singlestrand conformation polymorphism analysis. Cancer Res 1991, 51, 3356-3361.
20. 20. Hassapoglidou S, Diamandis EP, Sutherland DJA. Quantification of p53 protein in tumour cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene 1993, 8, 1501-1509.
21. 21. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunohistochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Meth 1992, 151, 237-244.
22. 22. Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem 1991, 37, 625-636.
23. 23. Hassapoglidou S, Diamandis EP. Antibodies to p53 tumour suppressor gene product quantified in cancer patient serum with a time-resolved immunofluorometric technique. Clin Biochem 1992, 25, 445-449.
24. 24. Angelopoulou K, Diamandis EP. Quantification of antibodies against the p53 tumour suppressor gene product in the serum of cancer patients. Cancer J 1993, 6, 315-321.
25. 25. Levesque MA, D'Costa M, Diamandis EP. Time-resolved immunofluorometric assay of p53 protein. Clin Chem 1995, 41, 1720-1729.
26. 26. Christopoulos TK, Diamandis EP. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 1992, 64, 342-346.
27. 27. Papanastasiou-Diamandi A, Christopoulos TK, Diamandis EP. Ultrasensitive thyrotropin immunoassay based on enzymatically amplified time-resolved fluoresence with a terbium chelate. Clin Chem 1992, 38, 545-548.
28. 28. Holstein M, Shormer B, Greenblatt M, et al. Somatic mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucl Acids Res 1996, 24, 141-146.